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OBJECTIVE—To elucidate the mechanism of the unique bene-
ﬁcial effect of intravitreal steroid therapy on diabetic macular
edema, we investigated the effect of locally administered triam-
cinolone acetonide (TA) on the expression of vascular endothe-
lial growth factor (VEGF)-A and its receptors in retinas of rats
with streptozotocin (STZ)-induced diabetes. We then correlated
the expression of these proteins with breakdown of the blood-
retinal barrier (BRB).
RESEARCH DESIGN AND METHODS—Thirty-two eyes of
16 diabetic and nondiabetic rats were divided into four groups.
TA was injected into the vitreous of the right eye, and saline was
injected into the left eye (control) 3.5 weeks after induction
of diabetes. Retinas were harvested 48 h following treat-
ment. mRNA and protein expression of VEGF-A, VEGF-A recep-
tor 1 (fms-like tyrosine kinase [FLT]-1), and VEGF-A receptor 2
(fetal liver kinase [FLK]-1) were determined by real-time RT-PCR
and immunohistochemistry. BRB permeability was quantitated
by measuring extravasated endogenous albumin and retinal
thickness.
RESULTS—Diabetes-induced retinal thickness and albumin ex-
travasation were signiﬁcantly reduced in TA-treated diabetic
retinas to a level similar to that in sham-treated nondiabetic eyes.
A close correlation between albumin leakage and increased
expression of both Vegf-a and Flk-1 was noted in the diabetic
retinas. TA downregulated the expression of Vegf-a and Flk-1 but
upregulated the expression of Flt-1. TA did not alter the expres-
sion of these genes in nondiabetic retinas.
CONCLUSIONS—Intravitreal injection of TA stabilizes the BRB
in association with regulation of Vegf-a, Flk-1, and Flt-1 expres-
sion in retinas in the early stages of diabetes. Diabetes 57:
1026–1033, 2008
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s the prevalence of diabetes progressively rises
throughout the world, improving the treatment
of macular edema, a common cause of loss of
vision from diabetic retinopathy (DR), has be-
come a major goal of ophthalmic research (1). Laser
treatment has been proven to reduce the risk of further
loss of vision in patients with clinically signiﬁcant macular
edema but is less effective in restoring vision once it
already has deteriorated. Moreover, laser treatment is an
intrinsically destructive procedure that itself can lead to
loss of vision through progressive enlargement of laser
scars with time (2).
Breakdown of the blood-retinal barrier (BRB) is an early
event in the pathogenesis of DR (3). When local compen-
satory mechanisms are overcome, frank vasogenic macu-
lar edema develops. The anatomical correlate responsible
for the BRB is the tight junction-associated proteins be-
tween retinal vascular endothelial cells (inner BRB) and
retinal pigment epithelial cells (outer BRB). It is strongly
suggested that the inner BRB (rather than the outer BRB)
is the primary site of the vascular leak that results in
diabetic macular edema in both human and animal studies
(4,5). In the retinas of rodents, the inner BRB has been
shown to become permeable to high–molecular weight
molecules in as little as 2 weeks after induction of diabetes
(6).
Vascular endothelial growth factor (VEGF)-A/vascular
permeability factor is believed to mediate increased vas-
cular permeability and colocalize with extravasated albu-
min in major retinal diseases such as DR (7,8) and
age-related macular degeneration (AMD) (9). VEGF-A ac-
tivates two tyrosine-kinase receptors, fms-like tyrosine
kinase-1 (FLT-1, vascular endothelial growth factor recep-
tor-1), and fetal liver kinase-1 (FLK-1, vascular endothelial
growth factor receptor-2) (10), which autophosphorylate
to initiate a signaling cascade that results in increased
microvascular permeability and angiogenesis (11). Inhibi-
tion of the VEGF-A overexpression is thus a potential
treatment for DR and AMD (12,13).
Triamcinolone acetonide (TA) is an intermediate acting
corticosteroid suspension. Intravitreal injections of TA
(IVTA) have shown remarkable efﬁcacy for the treatment
of advanced DR, in particular diabetic macular edema
(14,15). IVTA has been shown to inhibit VEGF-induced
breakdown of the BRB in rabbit and leukostasis in rat
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1026 DIABETES, VOL. 57, APRIL 2008models of DR (16,17). In a 2-year, double-masked, placebo-
controlled, randomized clinical trial, eyes with recalcitrant
diabetic macular edema involving the fovea that were
treated with IVTA had twice the chance of improving
vision and half the risk of further loss. However, a high
incidence of cataract and elevated intraocular pressure
was found in IVTA-treated eyes (18). If the unique beneﬁ-
cial effect of intravitreal steroid therapy on macular edema
is to be distinguished from its high risk of local adverse
events (glaucoma and cataract), the precise mechanism of
action of TA needs to be elucidated. In this study, we
determined the effect of IVTA on the expression of
VEGF-A and its receptors in a rodent model of early DR.
RESEARCH DESIGN AND METHODS
Animals. Male Sprague-Dawley (SD) rats (aged 8–10 weeks, ARC Laborato-
ries, Perth, Australia), weighing 240–250 g, were used in this study. The
animals were cared for in accordance with The Association for Research in
Vision and Ophthalmology statement for the use of animals in ophthalmic and
vision research. All animals were housed with environmental enrichment with
free access to food and water. Experimental procedures were conducted
under aseptic conditions and were approved by the Animal Ethics Committee
of the University of Sydney.
Induction of diabetes. Diabetes was induced with streptozotocin (STZ)
(Sigma) in SD rats according to the published protocol with slight modiﬁca-
tions (19,20). Rats were given a single dose of 65 mg/kg STZ i.p. in 100 mmol/l
citrate buffer (pH 4.5); weight- and age-matched nondiabetic control rats
received vehicle only. Eight animals were used per group for each set of
experiments. After STZ injection, body weights were recorded daily, and
diabetic status was conﬁrmed by tail vein blood glucose estimation using an
automated Accu-Chek glucometer (Roche Diagnostics, Indianapolis, IN) after
48 h. Rats with nonfasting blood glucose levels 13.8 mmol/ml were deemed
diabetic; those with lower values were excluded from this study. Maintenance
of a diabetic state was conﬁrmed by weekly tail vein blood glucose measure-
ments.
Treatment. Intravitreal treatment with TA or saline was performed 3.5 weeks
after induction of diabetes. Rats were divided into four experimental treat-
ment groups:
1. Diabetic eyes with IVTA treatment (IVTA-treated diabetic retinas, n  8,
right eyes)
2. Diabetic eyes with sham treatment (sham-treated diabetic retinas, n  8,
left eyes)
3. Nondiabetic eyes with IVTA treatment (IVTA-treated nondiabetic retinas,
n  8, right eyes)
4. Nondiabetic eyes with sham treatment (sham-treated nondiabetic retinas,
n  8, left eyes).
Intravitreal injection of TA. STZ-induced diabetic or nondiabetic animals
were anesthetized by isoﬂurane inhalation and a 4:1 mixture of ketamine
hydrochloride (80 mg/kg) and xylazine hydrochloride (4 mg/kg) i.m. Pupils
were dilated with one drop each of 0.5% tropicamide and 2.5% phenylephrine
hydrochloride. For additional topical anesthesia, 0.4% benoxinate-HCl of eye
drop was applied followed by 0.5% of levoﬂoxacin ophthalmic solution to
prevent infection. A single dose of 56 g TA (Kenacort-A 40, Victoria,
Australia) in a volume of 5.6 l (10 mg/ml) was injected into the vitreous of the
right eye with a 32-gauge microinjector (Hamilton, Reno, NV) under a
dissecting microscope (17). The contralateral eye, which received an equal
volume of saline, served as a sham-treated control. A 30-gauge needle was
used to make a punch incision 1 mm posterior to the temporal limbus, and a
microinjector needle was then inserted through the incision, 1.5 mm deep,
angled toward the optic nerve.
Preparation of retinas for histopathology/immunohistochemistry and
real-time RT-PCR. To detect VEGF-A, FLT-1, or FLK-1 antigen, the chest
cavity was opened following anesthesia as described above. A 20-gauge
perfusion cannula was introduced into the aorta via the left ventricle. Each rat
was perfused with 60 ml PBS at 37°C to clear the retinal vessels then perfused
with 40 ml 2% paraformaldehyde (PFA) in 0.1 mol/l phosphate buffer (PBS),
pH 7.4, after achieving drainage from the right atrium. Eyes were collected and
ﬁxed in 2% PFA overnight at 4°C. The ﬁxed eyes were processed routinely and
embedded in parafﬁn wax. To quantitate BRB breakdown (immunochemical
analysis of albumin leakage), rats were killed without perfusion.
For real-time RT-PCR studies, each retina was dissected and frozen
immediately in liquid nitrogen after perfusion with 100 ml PBS. Retinas were
stored at 80°C until extraction of RNA.
RNA isolation and characterization. Total RNA was isolated from individ-
ual retinas using TRI reagent (Sigma) and puriﬁed with a RNeasy Mini kit
(Qiagen, Victoria, Australia) according to the manufacturer’s instructions.
RNA concentrations and A260/A280 and A260/A230 ratios were measured using a
NanoDrop spectrophotometer. RNA integrity was assessed with an Agilent
2100 Bioanalyzer using an Agilent RNA 6000 Nano LabChip kit (Agilent
Technologies, Palo Alto, CA).
Two-step real-time RT-PCR. Reverse transcription (RT) was carried out
using a SuperScript III First-Stand Synthesis System for RT-PCR kit (Invitro-
gen, Australia). RNA (1 g) was reverse transcribed using 2.5 mol/l Oligo(dT)
primer after DNase I treatment according to the manufacturer’s instructions.
A non-RT control (minus RT) was performed for each RNA sample to test
genomic DNA contamination. The RT reaction was performed at 50°C for 50
min after denaturing at 65°C for 5 min. The RT reactions were terminated by
incubation at 85°C for 5 min.
Real-time PCR was performed using a Platinum SYBR Green qPCR
SuperMix-UDG kit (Invitrogen, Australia) on a Rotor-Gene 3000 real-time
thermal cycler according to the manufacturer’s instruction. The same real-
time PCR cycling condition was used for all target genes: 50°C for 2 min (UDG
reaction), 95°C for 2 min, 45 cycles of 95°C, 15 s; 60°C 20 s; 72°C 20 s. Melting
curve analysis and agarose gel electrophoresis were performed to conﬁrm the
purity of the qPCR products. All samples were performed in duplicate, and
replicate data were collected for further comparative analysis. The rat gene
speciﬁc primer pairs used for PCR are listed in Table 1.
Relative quantiﬁcation and statistical analysis. The BestKeeper program
(http://www.gene-quantiﬁcation.info) was used to determine the better refer-
ence gene between two widely used housekeeping genes (Gapdh and -actin)
for our study.
The relative quantiﬁcation analysis was performed using the Relative
Expression Software Tool (REST-MCS). The statistical signiﬁcance of varia-
tions in gene expression was analyzed by the pairwise ﬁxed reallocation
randomization test provided by the REST software. P values 0.05 were
considered signiﬁcant. Data are shown as means  SEM.
Morphological analysis. Retinal thickness was evaluated by using Image-Pro
Plus (IPP) 4.5 (Media Cybernetics, Silver Spring, MD) on 5 m hematoxylin
and eosin–stained sections. The eyes were cut vertically through the center of
the cornea and optic nerve, and both halves were embedded face down. Care
was taken to keep this cutting angle consistent for all eyes measured for
retinal thickness. Images of retinal sections were obtained, and the thickness
of both the retinas and sclera was measured using IPP4.5 with a reference
micrometer (Olympus, Australia) under the same conditions. Twenty lines
were manually drawn by an observer masked to the status of the rat from
which the eye was obtained, from the inner limiting membrane to the tips of
the photoreceptor outer segments for each of 20 sequential ﬁelds. The mean
scleral width was also calculated and found to be similar among the four
TABLE 1
Primers and product size for real-time RT-PCR
Target
genes
GenBank
accession no. Forward primer Reverse primer
Product size
(bp)
Gapdh NM_017008.3 5- GAGCTGAATGGGAAGCTCAC-3 5-AAAGGTGGAGGAGTGGGAGT-3 216
-actin NM_031144.2 5-AGCCATGTACGTAGCCATCC-3 5- CTCTCAGCTGTGGTGGTGAA3 228
Vegf-a NM_031836.1 5-AGAAACCCAATGAAGTGGTG-3 5- ACTCCAGGGCTTCATCATTG-3 177
Flt-1 NM_019306.1 5- TCCCTCAGCCTACCATCAAG-3 5- GAGAGTCAGCCACCACCAAT-3 207
Flk-1 NM_013062.1 5-ACAGCATCACCAGCAGTCAG-3 5- CCAAGAACTCCATGCCCTTA-3 168
The pairs of primers were designed according to rat gene sequences published in GenBank.
X. ZHANG AND COLLEAGUES
DIABETES, VOL. 57, APRIL 2008 1027groups, indicating that differences in retinal thickness were not due to
systematic sampling error (not shown).
Immunohistochemical detection of retinal VEGF-A, FLK-1, FLT-1, and
albumin. Standard indirect immunohistochemical methods were used to
detect leakage of albumin and the expression of VEGF-A, FLK-1, and FlT-1
(21). The parafﬁn-embedded retinal sections (5 m) were dewaxed and
dehydrated. The sections were then quenched with H2O2 blocker (Dako,
Australia) for 10 min at room temperature and washed three times in
Tris-buffered saline (TBS), pH 7.6.
For detection of albumin leakage in the retinas, the sections were
incubated with sheep anti-human albumin polyclonal antibody (Abcam,
Cambridge, U.K.) at a 1:500 dilution for1ha troom temperature. The sections
were further incubated with rabbit anti-sheep HRP-Streptavidin immunoglob-
ulin (Abcam) for 30 min at room temperature after three washes with TBS.
The sections were developed with 3-amino-9-ethylcarbazole chromogen (AEC;
Dako) for 3 min and counterstained with hematoxylin.
For detection of VEGF-A, FLK-1, and FLT-1, the sections were treated with
antigen retrieval solution (Dako) at 90°C for 10 min, subsequently cooled to
room temperature, and then quenched with H2O2 blocker. Sections were
incubated with rabbit anti-human polyclonal primary antibody [VEGF-A
(1:100); FLK-1 (1:200) or FLT-1 (1:50) antibody] (Abcam) for1ha troom
temperature. The sections were further incubated with goat anti-rabbit
HRP-Streptavidin immunoglobulin (Abcam) for 30 min at room temperature.
Slides were developed with diaminobenzidine (DAB; Dako) for 5 min and
counterstained with hematoxylin.
An isotype-matched negative control was used for all the antibodies (data
not shown).
Quantiﬁcation and statistical analysis of immunohistochemical stain-
ing. The peroxidase activity was visualized using DAB. The numbers of
VEGF-A–, FLT-1 –, and FLK-1–positive stained cells were counted per high-
power ﬁeld (400	) by using IPP4.5 as described previously (22,23). Brieﬂy, the
threshold of positive signal was deﬁned for each antibody for all the sections
following different treatments. Color signal above the threshold for each
antibody deﬁned was deemed to be positive, whereas any signal below the
threshold was regarded as negative. Analyses consisted of 20 ﬁelds per retina.
The entire retina was measured with reference to a micrometer (Olympus)
under the same condition sequentially. The number of positive signals versus
total cell numbers within each ﬁeld of the retina was determined with IPP 4.5
and was expressed as positive cell numbers per millimeter, as described
previously (24).
Extravasated albumin was visualized with AEC Chromogen. The threshold
of positive staining of albumin was deﬁned for all sections before automate
counting. The intravascular space was excluded by the analysis. The ratio of
the area of positive signal versus the total retinal area in each ﬁeld was
determined with IPP 4.5 and expressed as image arbitrary units (IAUs). All
images analyzed with IPP 4.5 were evaluated by an experienced masked
histopathologist.
Statistics for immunostaining. All data are presented as means  SEM.
One-way ANOVA was performed for statistical analysis (GraphPad Prism
Version 4.0, San Diego, CA). Differences between group means with P values
of 0.05 were regarded as being statistically different.
RESULTS
Retinal gene transcription of Vegf-a, Flk-1, and Flt-1.
Total RNA yield and quality. The average yields of
total RNA extracted from retinas in different groups were
comparable. The ratios of A260/A280 and A260/A230 for all
RNA samples were above 2 (2.10  0.005 and 2.03  0.002,
respectively), indicating limited protein and organic con-
taminants. RNA integrity number (RIN), obtained automat-
ically by the Agilent 2100 Expert software, was similar
between the diabetic and nondiabetic groups (8.7  0.2 vs.
8.4  0.01, P  0.88).
A single PCR fragment was obtained for each gene-
speciﬁc primer pair with the expected length as deter-
mined by 1.5% agarose gel electrophoresis. This was
conﬁrmed with a unique peak in the melting curve analysis
for each real-time PCR reaction (data not shown).
-actin was selected as a reference gene for this study
based on the results obtained from BestKeeper software
(Tables 2 and 3).
Relative changes in Vegf-a, Flk-1, and Flt-1 mRNA
expression. Diabetes and TA treatment differentially reg-
ulated the transcription of Vegf-a and its receptors. Tran-
scription of Vegf-a and Flk-1 was signiﬁcantly increased by
2.5- and 1.8-fold (PVegf-a  0.001 and PFlk-1  0.031),
respectively, but Flt-1 was downregulated 4.3-fold (PFlt-1
 0.005) in sham-treated diabetic retinas compared with
sham-treated nondiabetic retinas (Fig. 1A). Vegf-a and
Flk-1 transcription was signiﬁcantly downregulated 2.9-
and 2.0-fold, respectively (PVegf-a  0.030 and PFlk-1 
0.028); however, Flt-1 was signiﬁcantly upregulated 1.3-
fold (PFlt-1  0.002) with IVTA treatment (Fig. 1B). There
was no statistically signiﬁcant difference in the transcrip-
tion of Vegf-a and Flk-1 or Flt-1 between sham-treated and
FIG. 1. mRNA expression ratios for Vegf-a, Flk-1 and Flt-1. A: Sham-
treated diabetic retina/sham-treated nondiabetic retina. B: IVTA-
treated diabetic retina/sham-treated diabetic retina. C: IVTA-treated
nondiabetic retina/sham-treated nondiabetic retina.
TABLE 2
Results from BestKeeper descriptive statistical analysis showing variation in the capability potential (CP) values
Factor n GM (CP) AM (CP) Min (CP) Max (CP) SD (CP) CV (%CP)
Gapdh 32 19.75 19.88 16.06 16.50 1.66 8.35
-actin 32 14.01 14.03 13.00 15.80 0.59 4.17
Housekeeping gene expressions were assessed on total RNA templates isolated from retinas. GM (CP), the geometric mean of CP; AM (CP),
the arithmetic mean of CP; Min (CP) and Max (CP), the extreme values of CP; SD (CP), the SD of the CP; CV (%CP), the coefﬁcient of
variance expressed as a percentage of the CP level.
TABLE 3
Results from BestKeeper correlation analysis
BestKeeper vs. GAPDH 
-actin
r 0.909 0.815
P 0.001 0.003
Measures of correlation between the two candidate gene expressions
and the Bestkeeper in an index computed from the best candidate
genes.
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0.679, and PFlt-1  0.909) (Fig. 1C).
Retinal protein expression of VEGF-A, FLK-1, and
FLT-1. The expression of VEGF-A and its two receptors
(FLK-1 and FLT-1) was found predominantly in the gan-
glion cell layer, inner nuclear layer, and outer plexiform
layer of all four treatment groups. In nondiabetic retinas,
immunoreactivity against VEGF and FLK-1 was weak in
these layers in contrast to that in the diabetic retinas. The
expression of VEGF-A was increased by 1.8-fold in the
sham-treated diabetic retinas (37.44  0.74 vs. 20.40  0.44
positive cells/mm, P  0.0001) compared with sham-
treated nondiabetic retinas. The number of VEGF-A–pos-
itive cells was reduced by 32.1% in the IVTA-treated
diabetic retinas in contrast to the sham-treated diabetic
retinas (25.41  0.62 vs. 37.44  0.74 positive cells/mm,
P  0.001) (Fig. 2A). Similarly, FLK-1 expression was
increased by 1.6-fold in the sham-treated diabetic retinas
compared with that in sham-treated nondiabetic retinas
(53.17  1.08 vs. 32.95  0.47 positive cells/mm, P  0.0001).
The number of FLK-1–positive cells was signiﬁcantly de-
creased by 28.5% in the diabetic retinas with IVTA treatment
compared with that in sham-treated diabetic retinas (37.99 
0.71 vs. 53.17  1.08 positive cells/mm, P  0.0001) (Fig. 2B).
In contrast to the elevated levels of VEGF and FLK-1, FLT-1
expression was reduced by 37.5% in diabetic retinas (16.94 
0.76 vs. 27.09  0.56 positive cells/mm, P  0.0001) (Fig. 2C).
The number of FLT-1–positive cells in IVTA-treated diabetic
retinas increased by 1.2-fold compared with that in the
sham-treated diabetic retinas (20.87  0.73 vs. 16.94  0.76
positive cells/mm, P  0.0002) (Fig. 2C) but was still signif-
icantly less than both TA-treated or sham-treated nondiabetic
retinas (20.87  0.73 vs. 26.53  0.67 positive cells/mm;
20.87 0.73 vs. 27.09 0.56 positive cells/mm, P0.0001 for
both). No signiﬁcant difference was detected in the expres-
sion of VEGF-A and its receptors (FLK-1 and FLT-1) between
IVTA-treated and sham-treated nondiabetic retinas (PVEGF-A
 0.2641, PFLK-1  0.4792, and PFLT-1  0.5222) (Fig. 2A–C).
Retinal thickness analysis. There was no signiﬁcant
difference in retinal thickness between IVTA- and sham-
treated control eyes (147.28  1.23 vs. 147.60  1.40 m,
P  0.8627) (Fig. 3A and B). There was a 10% reduction in
the thickness of the IVTA-treated diabetic retinas com-
pared with the sham-treated diabetic retinas (148.20 
1.06 vs. 163.25  1.78 m, P  0.001) (Fig. 3C–E).
Sham-treated diabetic retinas were signiﬁcantly thicker
than sham-treated nondiabetic retinas (163.25  1.78 vs.
147.60  1.40 m, P  0.001) (Fig. 3E).
The effect of IVTA on albumin leakage. Extravascular
albumin was scarcely detected in the inner nuclear layer,
outer nuclear layer, and outer plexiform layer of nondia-
betic retinas (Fig. 4A and A1). In IVTA-treated and sham-
treated diabetic rats, albumin leakage was observed
mainly in the inner nuclear, outer plexiform, and outer
nuclear layers (Fig. 4B, B1, C, and C1). There was 3.6-fold
higher albumin expression in the sham-treated diabetic
retinas than the nondiabetic controls (17.20  1.78 vs.
4.84  1.58 IAU, P  0.0001) (Fig. 4D). However, albumin
expression in the extravascular space was signiﬁcantly
reduced by 63.5% in IVTA-treated diabetic retinas com-
pared with that in sham-treated diabetic retinas (6.27 
0.46 vs. 17.20  1.78 IAU, P  0.0001) (Fig. 4D). There was
no difference between the IVTA-treated nondiabetic reti-
nas versus sham-treated nondiabetic retinas (4.81  1.58
vs. 4.84  1.48 IAU, P  0.9590) (Fig. 4D).
DISCUSSION
In this study, we have demonstrated that IVTA inhibits the
increased expression of Vegf-a and Flk-1 in early diabetic
rat retinas. By contrast, Flt-1 expression was decreased in
early diabetic retinas but was upregulated following IVTA
treatment. A strong correlation of albumin leakage and
retinal thickness with the expression of Vegf-a and its
receptors was observed. These ﬁndings indicate that one
likely mechanism of action of IVTA on diabetic macular
edema is through the differential regulation of VEGF-A and
its receptors.
VEGF-A is a major regulator of angiogenesis and vascu-
FIG. 2. Quantiﬁcation analysis of VEGF-A, FLK-1, and FLT-1 distribu-
tion in the retina from different treatment groups. Number of positive
cells for VEGF-A (A), FLK-1 (B), and FLT-1 (C) per millimeter
(means  SEM, n  8). ***P < 0.001.
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ment of one of its receptors, FLK-1, in angiogenesis has
been widely demonstrated (11), but few studies have
addressed its role as a mediator of the BRB permeability.
Ojima et al. (25) demonstrated that VEGF-induced FLK-1
phosphorylation and its downstream signaling cascade
correlated with BRB breakdown and was inhibited by
EphA2/ephrinA1 both in vitro and in vivo. In our study, the
direct relationship between the expression of FLK-1 and
the vascular permeability/breakdown of the BRB was
further investigated in the diabetic retina. The overexpres-
sion of VEGF-A and FLK-1 that was found in the diabetic
retina in this study, in association with increased albumin
leakage, supports the hypothesis that FLK-1 is another
important permeability factor and regulator of BRB dys-
function in diabetes. These data are consistent with a
report that FLK-1 plays a critical role in breakdown of the
brain barrier (26).
The expression of another VEGF receptor, FLT-1, was
unexpectedly decreased in diabetic retinas and increased
FIG. 3. Retinal thickness was measured on H&E-stained sections at the similar location. The micrograph shows representative samples from
IVTA-treated nondiabetic retina (A), sham-treated nondiabetic retina (B), IVTA-treated diabetic retina (C), and sham-treated diabetic retina
(D). The yellow bar in A demonstrates one measurement of retinal thickness. E: Table showing mean ( SEM) retinal thickness (*** P < 0.001).
Original magniﬁcations 200. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL,
outer nuclear layer; RPE, retinal pigment epithelium layer; OS, inner and outer photoreceptor segment; CH, choroidal layer. To view a
high-quality digital representation of this image, go to http://dx.doi.org/db07-0982.
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tition between FLK-1 and FLT-1. FLT-1 on endothelial cells
may function as a negative regulator of FLK-1, acting as a
so-called “decoy” receptor that regulates the activity of
VEGFs on vascular endothelium by sequestering VEGF-A
and thus rendering it less available to bind to FLK-1 (27).
It is speculated that triggering of FLT-1 induces weak or
undetectable ligand-dependent tyrosine phosphorylation
in porcine aortic endothelial cells, whereas FLK-1 binding
induces a strong response (28). Furthermore, VEGF-A
mutants that bind selectively to FLK-1 are able to induce
mitogenesis and chemotaxis in endothelial cells, and vas-
cular permeability and angiogenesis in vivo, whereas
VEGF-A mutants that selectively bind to FLT-1 do not have
the activities stated above (29,30). In contrast to our
ﬁnding, increased expression of Flt-1 in the 6-month
STZ-induced diabetic rat retinas was reported by Hammes
et al. (31). In their study, increased Flt-1 mRNA levels
detected by in situ hybridization were found in the gan-
glion cell and both nuclear layers of diabetic samples only.
This apparent discrepancy may be explained by the differ-
ent durations of diabetes studied.
Diabetic macular edema is consistently reduced after
IVTA in human clinical trials, as is sensitively demon-
FIG. 4. Immunohistochemical analysis of retinal albumin distribution.
Albumin was detected (in red) within the vessels in sham-treated
nondiabetic retinas (A). A similar pattern of albumin distribution was
observed in IVTA-treated diabetic retina, but with slightly higher
expression in extra vascular space (B). Diffuse extravascular albumin
was observed in the inner nuclear, outer plexiform, and outer nuclear
layers in sham-treated diabetic retina (C). Extravasated albumin
(arrows in C) was marked green in panel A1, B1, and C1 (correspond-
ing to panels A, B, and C) by IPP4.5. Intravascular albumin was
excluded by the analysis (arrow heads in C1). D: Quantiﬁcation of
albumin distribution/leakage in the four treatment groups. Values were
presented as IAU. Data are means  SEM, n  8; *** P < 0.001. Original
magniﬁcations 400. To view a high-quality digital representation of
this image, go to http://dx.doi.org/db07-0982.
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study, the reduction of VEGF-A levels by IVTA treatment
that we observed is consistent with a reduction in levels of
extravasated albumin from the retinal vessels. This pro-
vides strong evidence that anti-VEGF therapy is an effec-
tive strategy for diabetic BRB dysfunction. Indeed, a
recent phase II study suggested that the VEGF-A inhibitor,
pegaptanib sodium, may also be efﬁcacious in the treat-
ment of diabetic macular edema (12).
Two hypotheses have been proposed to explain the
clinically established beneﬁcial effect of corticosteroids on
diabetic macular edema and the restoration of the BRB.
Firstly, corticosteroids may inhibit VEGF-A signaling by
blocking cytokine production, inducing leukocyte apopto-
sis (33), and, secondly, corticosteroids can directly induce
the barrier properties of interendothelial tight junction
complexes (34). A recent study suggests that corticoste-
roids may have relatively rapid effects, such as a decrease
in paracellular ﬂux and an increase in transepithelial
resistance, which correlates with an increase in tight
junction immunoreactivity at the cell border. A concomi-
tant decrease in occludin phosphorylation, potentially
countering the effects of VEGF-A, has also been noted
(35). Steroid treatment also appears to increase the ex-
pression of at least some tight junction-associated proteins
(36).
By providing a deeper understanding of the mechanisms
of action of intravitreal steroids on retinal disease, the
results of this study may be used to reﬁne their clinical
use. In a placebo-controlled, randomized clinical trial,
IVTA treatment doubled the chance of vision improvement
and halved the risk of further loss in eyes with advanced
diabetic macular edema. However, there was a signiﬁcant
risk of local adverse events, with 55% of eyes requiring
surgery to remove cataract over 2 years and 44% requiring
eye drops to control elevated intraocular pressure (18).
Anti-VEGF antibodies are another potential treatment for
diabetic retinopathy. Ranibizumab (37,38) and pegaptanib
sodium (13) have already been approved in the U.S. for
treatment of subretinal neovascularization; they are cur-
rently in advanced clinical development for diabetic reti-
nopathy, and more speciﬁc VEGF inhibitors are in the
pipeline. Presently, one of the disadvantages of these
drugs is that they need to be injected every 4–6 weeks, as
compared with every 6 months for triamcinolone (18).
However, it is likely that longer-acting preparations will
appear in due course. While VEGF inhibitors do not cause
corticosteroid-associated side effects, they may confer an
increased risk of systematic vascular adverse events (39).
There is also a suspicion that VEGF inhibitors may even-
tually cause retinal atrophy by blocking the cytokine’s
recently discovered neuroprotective action (40). On the
other hand, an increase in systemic adverse events has not
been detected in patients receiving intravitreal steroid
therapy, and there is some evidence to suggest that
steroids may have a protective effect on photoreceptors
(41), which could potentially offset any neurotoxic effect it
might have through inhibiting VEGF-A. How the known
adverse events of steroids will balance against the as yet
largely unknown safety proﬁle of speciﬁc VEGF inhibitors
is a subject that warrants careful clinical research in
future, as does the issue as to whether a long-acting
steroid combined with a speciﬁc VEGF inhibitor in low
doses might deliver the safest and most efﬁcacious clinical
response.
The integrity of the BRB can be assessed by various
techniques, each of which has advantages and limitations
(42). Extravasated albumin has been demonstrated to be a
precise indicator of the permeability of the blood-retinal
and blood-brain barriers (21,43). IPP is a sensitive image
analysis system that has been used to quantify subtle
changes in a number of studies (24,44). In this study,
immunolocalization of extravasated albumin was identi-
ﬁed at the light microscopic level and quantiﬁed using IPP,
providing a useful technique with which to study the effect
of IVTA on DR.
Rodent models do not mimic all aspects of human
diabetes, but such models are essential for the develop-
ment of new therapeutic approaches. While the short
duration of diabetic injury in this model (3.5 weeks)
imposes some limitations on the interpretation of the data,
similar ﬁndings relating to the function of VEGF-A and its
receptors on the BRB breakdown have also been observed
in humans with diabetes, providing justiﬁcation for our
studies in rodents (45).
This study adduces data that support the hypothesis that
intravitreal corticosteroid treatment improves diabetic
retinal edema by regulating the pathological expression
of VEGF-A and its receptors. We also show that IVTA
does not alter physiological VEGF-A, FLK-1, and FLT-1
levels in the normal retina. This raises the possibility that
combination therapy of low-dose anti-VEGF drugs and
steroids may offer advantages over anti-VEGF drugs alone
for the treatment of DR that is resistant to conventional
management.
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